US 12,263,217 B2
Nucleic acid stabilizing solution for vaccines, therapy, diagnostics, storage, and transport
Erik Avaniss Aghajani, Glendale, CA (US); John H. Phillips, Toronto (CA); Randal H. Rudderman, Atlanta, GA (US); and Robert Louis Mullen, Columbia, SC (US)
Assigned to Daykin Molecular Systems, LLC, Atlanta, GA (US)
Filed by Daykin Molecular Systems, LLC, Atlanta, GA (US)
Filed on Dec. 3, 2021, as Appl. No. 17/541,325.
Claims priority of provisional application 63/130,080, filed on Dec. 23, 2020.
Prior Publication US 2022/0193229 A1, Jun. 23, 2022
Int. Cl. A61K 39/39 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 2039/54 (2013.01); A61K 2039/55511 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A solution for stabilizing an injectable RNA-based vaccine having a lipid-based carrier, the solution consisting essentially of:
ethylenediaminetetraacetic acid (EDTA) having a molarity in the range of 0.026M to 1M;
tris(hydroxymethyl)aminomethane (TRIS) having a molarity in the range of 0.06M to 0.6M; and
a salt;
wherein the solution protects against degradation of the injectable RNA-based vaccine having a lipid based carrier added to the solution in a temperature range of +10 degrees C. to +45 degrees C. for a duration of 3 days to 40 days; and
wherein the solution is safe for injection into mammals.